News for Allakos Inc. (ALLK)

SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the ”œCompany”) ( ALLK), a biotechnology company that has been developing antibodies f

**media[564846]**

**media[537997,537998]**

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting ...

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling over 100 points on Monday. The Dow traded up 0.22% to 44,521.81 while the NASDAQ f...

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index edging higher on Monday. The Dow traded up 0.04% to 44,440.59 while the NASDAQ...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 600 points on Monday. Following the market opening Monday, the Dow traded down 0....

Allakos Inc. (ALLK), Monday announced disappointing topline results from its phase 1 clinical trial, evaluating AK006 in adult patients with moderate-to-severe chronic spontaneous urticarial.

”“ AK006 did not demonstrate therapeutic activity in CSU ”“”“ Allakos will discontinue further development of AK006, reduce workforce by 75% and explore stra

Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and CSU. Read why I'm bullish on ALLK stock.

The rising prevalence of urticaria is fueling market growth, with increased allergic responses and lifestyle shifts playing key roles. Advances in biologic...

The exosome market is fueled by several significant factors, such as the rising incidence of chronic diseases, improvements in diagnostic methods, and...

Allakos (ALLK) stock rose in premarket after positive Phase 1 trial data for a subcutaneous version of its lead asset AK006. Read more here.

The dynamics of the atopic dermatitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies. The rising...

Blueprint Medicines generates strong revenue growth from its FDA-approved product AYVAKIT, reporting $92.5 million in Q1'24 net product revenues. Read more here.

Read Analysts’ Downgrades for May 10th (ABEV, ABOS, ABSI, ADSE, AKBA, AKRO, ALCO, ALGS, ALLK, ALRM) at ETF Daily News

This article focuses on the influences towards a biotech company's share price, rather than their value. Read what to know about biotech catalysts here.

GuruFocus Article or News written by Barry Cohen and the topic is about: Company's valuation doubled in two years, though the stock is down this year